TrialInvestigational new drugs2025

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.

Karen A Autio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.